Jeff Schaffnit discusses Sanofi's advancements in BTK inhibitors and promising results for hemophilia A therapies at ASH 2025 ...

Sanofi and its blockbuster drug Dupixent has by the thinnest of margins returned to the top spot for TV drug ad spending in October, beating out fierce rival AbbVie and its immunology drug Rinvoq, ...

MUMBAI, May 16 (Reuters) - Glenmark Pharma is in licensing deal with Sanofi , two television channels reported on Monday. Sanofi will have exclusive marketing rights in Europe, USA and Japan, ...

Sanofi is shelling out $1.15 billion to acquire Vicebio, a startup with a pipeline of respiratory vaccine candidates and a platform technology that will support the pharmaceutical giant’s ambitions to ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor as OpenAI's agentic models grow in capabilities. OpenAI's "Deep Research" tool is already incredibly promising for Sanofi ...

Sanofi and Regeneron’s immunology blockbuster Dupixent ended the year nabbing the highest TV ad spend for December. Spend over the festive month for the drug was up $3.3 million on November, helping ...

Market conditions continue to pose challenges for startups trying to raise money. Some of these companies might be a fit for Sanofi’s corporate venture capital arm, which the pharmaceutical giant has ...

Sanofi's stock has shown volatility, but recent gains are driven by Dupixent's success, the Consumer Health spin-out, and promising pipeline assets. Despite a Q323 earnings miss and downbeat guidance ...